Bendroflumethiazide

Bendroflumethiazide

Systematic (IUPAC) name
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Pregnancy cat.	Risk neonatal thrombocytopenia in 3rd trimester
Legal status	POM (UK)
Routes	Oral
Pharmacokinetic data
Bioavailability	100%
Protein binding	96%
Metabolism	extensive
Half-life	3-4 hours
Identifiers
CAS number	73-48-3 Y
ATC code	C03AA01
PubChem	CID 2315
DrugBank	APRD00666
ChemSpider	2225 Y
UNII	5Q52X6ICJI Y
KEGG	D00650 Y
ChEBI	CHEBI:3013 Y
ChEMBL	CHEMBL1684 Y
Chemical data
Formula	C15H14F3N3O4S2
Mol. mass	421.415 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23) Y Key:HDWIHXWEUNVBIY-UHFFFAOYSA-N Y
N (what is this?)  (verify)

Bendroflumethiazide (INN), formerly bendrofluazide (BAN), is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide (bendrofluazide) is a thiazide diuretic which works by inhibiting sodium absorption at the beginning of the distal convoluted tubule (DCT). Potassium is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

Common adverse effects

• postural hypotension
• hyponatraemia, hypokalaemia, hypercalcaemia
• gout
• impaired glucose tolerance
• impotence

Rare adverse effects

• thrombocytopenia
• agranulocytosis
• photosensitivity rash
• pancreatitis